Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B, et al
(4) Derivatives optimizing lipophilicity and absorption
Patients with Hepatic Impairment Dulaglutide systemic exposure decreased by 23, 33 and 21% for mild, moderate and severe hepatic impairment groups, respectively, compared to subjects with normal hepatic function, and Cmax was decreased by a similar magnitude (Figure 1) [see Use in Specific Populations (8.7)]
The study has not yet been published in a peer-reviewed scientific journal, but was presented at the European Congress on Obesity (ECO2026) from May 1215
US$ 24.05
US$ 28.28
US$ 26.10
US$ 24.62
US$ 23.45
